San Diego Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes

San Diego, CA US
February 3, 2023 to February 4, 2023

This CME-accredited activity “San Diego Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes” features leading experts in thoracic malignancies who will provide a comprehensive overview of current and emerging strategies for management of lung cancer (NSCLC, SCLC), mesothelioma, and thymic malignancies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with thoracic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in molecular testing and targeted-therapies for thoracic oncology. Expert faculty will aim to place the role of different therapeutic agents in clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. 

The symposium will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:

  •  Neoadjuvant and adjuvant treatment of non-small cell lung cancer (NSCLC) including specific roles of immune-checkpoint inhibitors, targeted therapy, and chemotherapy.
  • Role of different platforms, including next generation sequencing and PD-L1 assessment to identify treatment options in NSCLC.
  • Appropriate use of systemic therapy in small cell lung cancer (SCLC)
  • Novel approaches to the treatment of mesothelioma and thymic malignancies
  • Trends, challenges, controversies, and limitations of precision oncology approaches and targeted therapies in management of thoracic malignancies.

Target Audience

  • Medical Oncologists
  • Surgeons
  • Radiation Oncologists,
  • Pathologists Oncology Fellows
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review frequent molecular abnormalities in NSCLC, and appropriate testing and treatment
  • Outline efficacy and toxicities of immune checkpoint inhibitors, targeted therapy, and other chemotherapy agents in management of management of NSCLC
  • Identify the role of neoadjuvant and adjuvant systemic therapy options in curative-intent treatment of NSCLC, including the role of chemotherapy, immune checkpoint inhibitors and targeted therapy.
  • Incorporate appropriate sequencing of treatment options in patients with mesothelioma and thymic malignancies.
  • Integrate emerging evidence in precision oncology into testing and treatment paradigms for treatment of thoracic malignancies.
Course summary
Available credit: 
  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.
Course opens: 
11/01/2022
Course expires: 
04/01/2023
Event starts: 
02/03/2023 - 3:00pm PST
Event ends: 
02/04/2023 - 4:30pm PST
Cost:
$300.00
Add to calendar: 

DAY 1 - FEBRUARY 03, 2023

All General Sessions take place in Bayview II & III

All Exhibits & breaks take place in Mission Ballroom
 
1:45 PM to 2:45 PM Registration/Networking/Exhibits

2:45 PM to 3:00 PM Welcome note from the conference chairs - Drs. Kristin Higgins and Sandip Patel

3:00 PM to 4:15 PM Session 1: Molecular Mysteries in Cancer:  Controversies in Biomarker Assessment 
Moderator: Dara Aisner, MD, PhD
3:00 PM to 3:15 PM Case Intro:  The Case of the Missing ALK- Dara Aisner, MD, PhD
3:15 PM to 3:30 PM Optimization in Tissue Acquisition and Pathologic Assessment- George Cheng, MD, PhD
3:30 PM to 3:45 PM Systemic Management of ALK-Rearranged NSCLC- Sai-Hong Ignatius Ou MD,PhD
3:45 PM to 4:00 PM Clinical Utility of Circulating Tumor DNA in NSCLC - Aditya Sarvaria, MD
4:00 PM to 4:15 PM Case Panel

4:15 PM to 5:15 PM Session 2: Early Stage NSCLC
Moderator: Misako Nagasaka, MD, PhD
4:15 PM to 4:30 PM Advances in Neoadjuvant Treatment in NSCLC – Misako Nagasaka, MD, PhD
4:30 PM to 4:45 PM Surgical Management after Neoadjuvant Treatment in NSCLC- Hari Keshava, MD
4:45 PM to 5:00 PM Radiotherapy in Early Stage NSCLC- Arya Amini, MD
5:00 PM to 5:15 PM Panel discussion - Session speakers

6:00 PM to 8:00 PM - Dinner/Product Theater/Sponsored talks

6:15 PM to 7:00 PM in Bayview I - Innovation Theater by AstraZeneca Pharmaceuticals: Dual Immunotherapy + Platinum-Based Chemotherapy for the Treatment of mNSCLC and A Challenging Case in Resectable NSCLC

Speaker - Ani Balmanoukian, MD, Director of Thoracic Oncology. The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles

This is an industry-sponsored educational activity, not part of the CME activity. This program does not provide CME Credits.

DAY 2 - FEBRUARY 04, 2023

All General Sessions take place in Bayview II & III

All Exhibits & breaks take place in Mission Ballroom

7:00 AM to 8:30 AM Breakfast and registration/Networking/Exhibits

8:30 AM to 9:30 AM Session 3: New Horizons in Locally Advanced NSCLC
Moderator: Salma Jabbour, M.D., FASTRO
8:30AM to 8:45AM RT and Immunotherapy Synergy in Unresectable NSCLC- Salma Jabbour, MD, FASTRO
8:45 to 9:00AM MRD in Locally Advanced NSCLC- Aadel Chaudhuri, MD PhD
9:00AM to 9:15AM Immunotherapy Combinations: Building on the PACIFIC Paradigm- Kathryn Gold, MD
9:15 AM to 9:30 AM Panel discussion - Session speakers

9:30 AM to 9:50 AM Break & Exhibits

9:50 AM to 11:05 AM Session 4: Use of Immunotherapy in Metastatic NSCLC
Moderator: Narjust Florez, MD                    
9:50 AM to 10:15 AM Systemic Immunotherapy Options in Metastatic Lung Cancer – Narjust Florez, MD 
10:15 AM to 10:30 AM Oligometastatic Radiotherapy Options-  Steven Lin, MD, PhD
10:30 AM to 10:45 AM Biomarkers for Immunotherapy use in NSCLC- Sai-Hong Ignatius Ou MD, PhD
10:45 AM to 11:05 AM Panel discussion - Session speakers 

11:05 AM to 12:20 AM Session 5: Targeted Therapy in NSCLC
Moderator: Jack West, MD     
11:05 AM to 11:20 AM Advances in Targeted Therapy in metastatic NSCLC – Andy (Sew-Chung) Jang, MD
11:20 AM to 11:35 AM Use of Targeted Therapy in Localized NSCLC - Jonathan Riess MD, MS
11:35 AM to 11:50 PM RT and targeted therapy: CNS and Extra-Cranial Considerations- Jona Hattangandi-Gluth, MD PhD
11:50 AM to 12:20 PM Case Panel:  Targeting Resistance in NSCLC - Session Speakers     

12:20 PM to 1:20 PM Lunch & Exhibits

12:30 PM to 1:15 PM in Bayview I - Innovation Theater by Regeneron Pharmaceuticals: Personalizing treatment for adult patients with advanced NSCLC

Speaker - Clifton P. Layman, DO, Chief of Hematology/Oncology Services, Tripler Army Medical Center, Honolulu, HI

  • This program will review:
    • Approaches to personalizing care in patients with advanced NSCLC
    • Clinical evidence from two large phase 3 clinical trials in certain patients with advanced NSCLC
    • Exploring hypothetical patient profiles

This is an industry-sponsored educational activity, not part of the CME activity. This program does not provide CME Credits.

1:20 PM to 2:35 PM Session 6: Mesothelioma and Thymic Malignancies
Moderator: Kavitha Ramchandran, MD
1:20 PM to 1:35 PM- Multimodal Treatment for Malignant Pleural Mesothelioma (MPM): Surgical Treatment Options in 2023- Jeffrey Velotta, MD
1:35 PM to 1:50 PM Advances in Treatment in Thymic Malignancies: Kavitha Ramchandran, MD
1:50 PM to 2:05 PM Systemic Immunotherapy Approaches to Mesothelioma- Matthew Gubens MD, MS
2:05 PM to 2:20 PM Role of RT in Thymoma and Thymic Malignancies- Stephen Chun, MD
2:20 PM to 2:35 PM Case Panel discussion- Session Speakers

2:35 PM to 3:20 PM Session 7: Small Cell Lung Cancer 
Moderator: Nagla Abdel Karim, MD 
2:35 PM to 2:50 PM Advances in Immunotherapy in SCLC – Nagla Abdel Karim, MD
2:50 PM to 3:05 PM Management of Refractory SCLC – Ana Velazquez Manana, MD
3:05 PM to 3:20 PM Role of RT in SCLC – Percy Lee, MD

3:20 to 3:30 PM Concluding remarks – Drs. Kristin Higgins and Sandip Patel

 

Hyatt Regency Mission Bay
1441 Quivira Rd
San Diego, CA 92109
United States

A limited number of rooms have been booked at the Hyatt Regency Mission Bay for participants of this conference. Please book your hotel room by Tuesday, January 3, 2023, to receive the discounted room rate through this link: https://www.hyatt.com/en-US/group-booking/SANIS/G-BINA

CUT-OFF DATE- Tuesday, January 3, 2023 

PARKING: 

The overnight parking has been discounted to is currently $45.00, with the group discount, the overnight parking is $35.00.

GUEST ROOM TAXES 

The Guest Room Rates are quoted exclusive of applicable state and local taxes (which are currently ten point five percent (10.5%) State Sales Tax and City Occupancy Tax, two percent (2%) San Diego Tourism Marketing District Assessment, and $0.55 State of California Tourism Assessment), applicable service fees, and/or Hotel-specific fees in effect at the time of the Event. 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Kristin Higgins, MD

has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Janssen Pharmaceuticals;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Jazz Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with RefleXion Medical;.

Sandip Patel, MD

has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with AstraZeneca/MedImmune;.
has a financial relationship (Grant Or Contract) with Roche/Genentech;.
has a financial relationship (Grant Or Contract) with Merck;.
Speaker/Topic Presenter(s)

Nagla Abdel Karim, MD, PhD

has a financial relationship (Professional Services) with Jazz, Regeneron, Amgen;.
has a financial relationship (Other) with BMS, Exelixis, Pfizer, Astra Zeneca;.

Dara Aisner, MD, PhD

has a financial relationship (Professional Services) with Loxo/Eli Lilly;.
has a financial relationship (Professional Services) with Sanofi Genzyme;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Genentech;.

Arya Amini, MD

has no relevant financial relationships to disclose at this time.

Aadel Chaudhuri, MD PhD

has a financial relationship (Independent contractor) with Daiichi Sankyo;.
has a financial relationship (Independent contractor) with Guidepoint;.
has a financial relationship (Other) with Illumina;.
has a financial relationship (Independent contractor) with DeciBio;.
has a financial relationship (Stock) with LiquidCell Dx;.
has a financial relationship (Independent contractor) with Tempus Labs;.
has a financial relationship (Independent contractor) with AlphaSights;.
has a financial relationship (Stock) with Droplet Biosciences;.
has a financial relationship (Independent contractor) with Roche;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Stock Options) with Geneoscopy;.

George Cheng, MD PHD

has a financial relationship (Professional Services) with Intuitive;.
has a financial relationship (Professional Services) with Olympus;.
has a financial relationship (Professional Services) with Boston Scientific;.
has a financial relationship (Professional Services) with Cook;.
has a financial relationship (Professional Services) with Siemens ;.
has a financial relationship (Professional Services) with Pulmonx;.
has a financial relationship (Professional Services) with Medtronic;.
has a financial relationship (Professional Services) with ERBE;.

Stephen Chun

has a financial relationship (Independent contractor) with Curio Science, Inc;.
has a financial relationship (Travel) with ViewRay, Inc;.
has a financial relationship (Independent contractor) with AstraZeneca, PLC;.

Narjust Florez, Associate Director of Cancer Care Equity Program, Thoracic Medical Oncologist

has a financial relationship (Professional Services) with Neogenomics;.
has a financial relationship (Professional Services) with Astrazeneca;.
has a financial relationship (Professional Services) with DSI;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Pfizer;.

Kathryn Gold

has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Regeneron;.

Matthew Gubens

has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Gemzyme;.
has a financial relationship (Independent contractor) with Surface;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Cardinal Health;.
has a financial relationship (Independent contractor) with iTeos;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Guardant;.

Jona Hattangadi-Gluth

has no relevant financial relationships to disclose at this time.

Salma Jabbour, M.D. Professor & Vice Chair of Clinical Research and Faculty Development

has a financial relationship (Professional Services) with Advarra;.
has a financial relationship (Professional Services) with Radialogica;.
has a financial relationship (Professional Services) with Merck & Co, Inc;.
has a financial relationship (Professional Services) with IMX Medical;.
has a financial relationship (Professional Services) with Novocure;.

Andy Jang, Assistant Professor of Medicine

has no relevant financial relationships to disclose at this time.

Hari Keshava, MD, MS

has no relevant financial relationships to disclose at this time.

Percy Lee, M.D.

has a financial relationship (Professional Services) with Varian;.
has a financial relationship (Professional Services) with Viewray;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Genentech;.

Steven Lin, MD, PhD

has a financial relationship (Grant Or Contract) with STCube Pharmaceuticals;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with XRAD Therapeutics;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Grant Or Contract) with Beyond Spring Pharmaceuticals;.

Misako Nagasaka

has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Caris Life Sciences;.
has a financial relationship (Travel) with AnHeart Therapeutics;.
has a financial relationship (Professional Services) with EMD Serono;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Professional Services) with Blueprint Medicine;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Janssen;.

Sai-Hong Ou

has no relevant financial relationships to disclose at this time.

Kavitha Ramchandran, MD

has a financial relationship (Other) with Varian Medical Systems -;.
has a financial relationship (Other) with Group well;.
has a financial relationship (Other) with Pathomiq;.
has a financial relationship (Other) with Curio Science;.

Jonathan Riess, MD, MS

has a financial relationship (Professional Services) with Blueprint;.
has a financial relationship (Professional Services) with Jazz Pharmaceuticals;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with EMD Serano;.
has a financial relationship (Professional Services) with Turning Point;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Biodesix;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Beigene;.

Aditya Sarvaria, MD

has no relevant financial relationships to disclose at this time.

Ana Velazquez Manana, MD MSc

has a financial relationship (Stock) with Corbus Pharmaceuticals;.
has a financial relationship (Independent contractor) with Astra Zeneca;.

Jeffrey Velotta, Jeffrey B. Velotta, MD, FACS

has no relevant financial relationships to disclose at this time.
Moderator(s)

Nagla Abdel Karim, MD, PhD

has a financial relationship (Other) with BMS, Exelixis, Pfizer, Astra Zeneca;.
has a financial relationship (Professional Services) with Jazz, Regeneron, Amgen;.

Dara Aisner, MD, PhD

has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Loxo/Eli Lilly;.
has a financial relationship (Professional Services) with Sanofi Genzyme;.
has a financial relationship (Professional Services) with Takeda;.

Narjust Florez, Associate Director of Cancer Care Equity Program, Thoracic Medical Oncologist

has a financial relationship (Professional Services) with Astrazeneca;.
has a financial relationship (Professional Services) with Neogenomics;.
has a financial relationship (Professional Services) with DSI;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Merck;.

Salma Jabbour, M.D. Professor & Vice Chair of Clinical Research and Faculty Development

has a financial relationship (Professional Services) with Novocure;.
has a financial relationship (Professional Services) with Advarra;.
has a financial relationship (Professional Services) with Radialogica;.
has a financial relationship (Professional Services) with Merck & Co, Inc;.
has a financial relationship (Professional Services) with IMX Medical;.

Misako Nagasaka

has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Caris Life Sciences;.
has a financial relationship (Travel) with AnHeart Therapeutics;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Professional Services) with Blueprint Medicine;.
has a financial relationship (Professional Services) with EMD Serono;.

Kavitha Ramchandran, MD

has a financial relationship (Other) with Varian Medical Systems -;.
has a financial relationship (Other) with Group well;.
has a financial relationship (Other) with Pathomiq;.
has a financial relationship (Other) with Curio Science;.

Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA

has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Takeda;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Mirati;.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from the following companies:

  • Exact Sciences
  • Novartis Pharmaceuticals Corporation

Available Credit

  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.

Price

Cost:
$300.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $300

Non-physician HCP (non-industry) - $150

Industry representatives - $850

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
No refunds will be issued if registration is cancelled after that date.  
No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.